Healthcare -
Medical - Devices - NASDAQ - US
$ 17.91
2.1 %
$ 647 M
Market Cap
-14.0
P/E
1. INTRINSIC VALUE
Balance Sheet
CeriBell, Inc.
| Current Assets | 217 M |
| Cash & Short-Term Investments | 194 M |
| Receivables | 10.9 M |
| Other Current Assets | 12 M |
| Non-Current Assets | 8.14 M |
| Long-Term Investments | 0 |
| PP&E | 4.44 M |
| Other Non-Current Assets | 3.7 M |
| Current Liabilities | 13 M |
| Accounts Payable | 1.14 M |
| Short-Term Debt | 1.09 M |
| Other Current Liabilities | 10.8 M |
| Non-Current Liabilities | 21.3 M |
| Long-Term Debt | 20.9 M |
| Other Non-Current Liabilities | 386 K |
EFFICIENCY
Earnings Waterfall
CeriBell, Inc.
| Revenue | 65.4 M |
| Cost Of Revenue | 8.69 M |
| Gross Profit | 56.8 M |
| Operating Expenses | 96.5 M |
| Operating Income | -39.7 M |
| Other Expenses | 746 K |
| Net Income | -40.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
CeriBell, Inc.
| Net Income | -40.5 M |
| Depreciation & Amortization | 1.14 M |
| Capital Expenditures | -1.34 M |
| Stock-Based Compensation | 5.41 M |
| Change in Working Capital | -3.17 M |
| Others | 3.19 M |
| Free Cash Flow | -36.4 M |
Wall Street Analysts Price Targets
CeriBell, Inc.
Wall Street analysts predict an average 1-year price target for CBLL of $30 , with forecasts ranging from
a
low of
$30 to a high of $30 .
CBLL Lowest Price Target
Wall Street Target
30 USD
67.50%
CBLL Average Price Target
Wall Street Target
30 USD
67.50%
CBLL Highest Price Target
Wall Street Target
30 USD
67.50%
4. DIVIDEND
ANALYSIS
CBLL does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
CeriBell, Inc.
Sold
0-3 MONTHS
1.23 M USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Ceribell to Participate in the William Blair 45th Annual Growth Stock Conference
SUNNYVALE, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming William Blair 45th Annual Growth Stock Conference. The presentation will take place on Tuesday, June 3, 2025, at 7:20 a.m. Pacific Standard Time / 9:20 a.m. Central Standard Time.
globenewswire.com
- 1 month ago
CeriBell, Inc. (CBLL) Q1 2025 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Xingjuan Chao - Co-Founder and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Margaret Andrew - William Blair Josh Jennings - TD Cowen John Young - Canaccord Jeffrey Cohen - Ladenburg Thalmann Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q1 2025 Earnings Call.
seekingalpha.com
- 1 month ago
Ceribell Reports First Quarter 2025 Financial Results
SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.
globenewswire.com
- 1 month ago
Ceribell to Participate in the Bank of America Securities 2025 Health Care Conference
SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming Bank of America Securities 2025 Health Care Conference. The presentation will take place on Wednesday, May 14, 2025, at 10:55 a.m. Pacific Standard Time / 1:55 p.m. Eastern Standard Time.
globenewswire.com
- 1 month ago
Ceribell Receives FedRAMP® High Authorization, Expanding Approval for Its AI-Powered Point-of-Care EEG Across Federal Healthcare Systems
Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures SUNNYVALE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP® (Federal Risk and Authorization Management Program) High authorization from the U.S. government.
globenewswire.com
- 1 month ago
Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025.
globenewswire.com
- 1 month ago
CBLL Stock Falls Despite FDA Clearance for Pediatric Clarity Algorithm
Ceribell secures FDA clearance for Clarity algorithm in pediatric patients, expanding rapid seizure detection capabilities and enhancing critical care efficiency.
zacks.com
- 2 months ago
FDA Clears Ceribell's Clarity™ Algorithm for Pediatric Patients, Making Ceribell the First and Only FDA-Cleared AI Technology for Detection of Electrographic Seizures in Patients Ages 1 Year and Older
SUNNYVALE, Calif., April 15, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its next generation Ceribell Clarity™ algorithm for the detection of electrographic seizures in patients ages 1 and older.
globenewswire.com
- 2 months ago
CeriBell, Inc. (CBLL) Q4 2024 Earnings Call Transcript
CeriBell, Inc. (NASDAQ:CBLL ) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Brian Johnston - Gilmartin Group Xingjuan Chao - President and Chief Executive Officer Scott Blumberg - Chief Financial Officer Conference Call Participants Stephanie Piazzola - Bank of America Robert Marcus - JPMorgan Chase & Co. Macauley Kilbane - William Blair & Company Joshua Jennings - TD Cowen William Plovanic - Canaccord Genuity Corp. Operator Operator Hello, and thank you for standing by. At this time, I would like to welcome you to the CeriBell Q4 2024 Earnings Call.
seekingalpha.com
- 3 months ago
Ceribell Reports Fourth Quarter and Full Year 2024 Financial Results
SUNNYVALE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the fourth quarter and full year ended December 31, 2024.
globenewswire.com
- 3 months ago
CeriBell: A Leader In AI-Powered Seizure Detection
AI is revolutionizing clinical diagnostics, achieving high accuracy and speed in detecting diseases like Crohn's, fatty liver, coronary artery disease, sepsis, and cancer. CeriBell's AI-powered EEG system offers rapid seizure diagnosis, significantly reducing setup time and ICU stays, thus lowering patient morbidity, mortality, and healthcare costs. Clarity Pro algorithm, FDA-approved in 2023, enhances non-convulsive seizure diagnosis, enabling faster response by ancillary healthcare workers and improving clinical outcomes.
seekingalpha.com
- 3 months ago
Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference
SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 a.m. Eastern Standard Time.
globenewswire.com
- 3 months ago
8. Profile
Summary
CeriBell, Inc. CBLL
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 647 M
Dividend Yield
0.00%
Description
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company develops Ceribell System, a novel, point-of-care EEG platform to address the unmet needs of patients in the acute care setting. It also offers EEG disposable headbands; and pocket-sized battery-operated recorders. The company was formerly known as Brain Stethoscope, Inc. and changed its name to CeriBell, Inc. in August 2015. The company was incorporated in 2014 and is based in Sunnyvale, California.
Contact
360 North Pastoria Avenue, Sunnyvale, CA, 94085
https://ceribell.com
IPO
Date
None
Employees
281
Officers
Ms. Baharan Kamousi Ph.D.
Senior Vice President of Data Science
Dr. Raymond Woo Ph.D.
Chief Technology Officer
Mr. Dan Rogy
Senior Vice President of Operations
Ms. Louisa Daniels J.D., M.B.A.
General Counsel
Mr. Brian P. Price
Senior Vice President of Marketing
Dr. Josef Parvizi M.D., Ph.D.
Co-Founder, Chief Medical Advisor & Director
Mr. Sean Manni
Senior Vice President of Sales
Mr. Scott Blumberg
Chief Financial Officer
Ms. Kristie Rodenbush
Chief People Officer
Dr. Xingjuan Chao Ph.D.
Co-Founder, President, Chief Executive Officer & Director